Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 24;10(1):53-7.
doi: 10.5114/aoms.2014.40733. Epub 2014 Feb 23.

The risk of cholelithiasis in patients after heart transplantation

Affiliations

The risk of cholelithiasis in patients after heart transplantation

Piotr Wegrzyn et al. Arch Med Sci. .

Abstract

Introduction: Extended immunosuppressive treatment in patients after heart transplantation modifies etiopathogenesis and occurrence of many diseases in this population. The aim of the present study was to evaluate the frequency and to define risk factors for cholelithiasis after heart transplantation (HTX).

Material and methods: The study population consisted of 176 subjects. Of them, 24 patients (group A) presented with symptomatic cholelithiasis. Another group of 24 patients without cholelithiasis (group B) served as controls. Both groups were similar with respect to age, gender and follow-up after the transplant. Clinical interview, surgical and hospitalization data were collected from medical records.

Results: The groups did not differ in demographic features. There were statistical differences (p < 0.05) between group A and B in rejection reaction, doses of immunosuppressive drugs, type 2 diabetes, serum lipid disorders and acute rejection episodes. These events were caused by modification of treatment, especially the immunosuppressive regimen. Group A consisted of 75% men and 25% women. The frequency of symptomatic cholelithiasis was 11.7% in men and 27.3% in women, on average 19.5%. Mean time to cholelithiasis following HTX was 37.9 ±4.9 (Me = 41.5) months, 27.7 ±8.2 (Me = 30.0) months in women and 41.3 ±5.9 (Me = 41.5) months in men. The female to male ratio was 2.3: 1.

Conclusions: Cholelithiasis following HTX was significantly more frequent as compared with the non-transplant population. Patients with cholelithiasis required more aggressive immunosuppression because of more frequent episodes of acute transplant rejection. Patients with cholelithiasis significantly more frequently showed increased glycemia and blood lipids, which could be the side effect of intensive immunosuppressive therapy.

Keywords: cholelithiasis; cyclosporine A; immunosuppression; transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve: long-term surviving proportion between group A and group B. Log-rank test statistic = –0.905054, p = 0.36544

Similar articles

Cited by

References

    1. Task Force Members. McMurray JJ, Adamopoulos S, Anker SD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847. - PubMed
    1. Feola M, Lombardo E, Testa M, et al. Prognostic factors of mid-term clinical outcome in congestive heart failure patients discharged after acute decompensation. Arch Med Sci. 2012;8:462–70. - PMC - PubMed
    1. Sekhri V, Sanal S, DeLorenzo L, et al. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7:546–54. - PMC - PubMed
    1. Aliabadi A, Cochrane AB, Zuckermann AO. Current strategies and future trends in immunosuppression after heart transplantation. Curr Opin Organ Transplant. 2012;17:540–5. - PubMed
    1. Lord RV, Ho S, Coleman MJ, et al. Cholecystectomy in cardiothoracic organ transplant recipients. Arch Surg. 1998;133:73–9. - PubMed

LinkOut - more resources